Skip to main content
. 2022 Jan 3;24:10. doi: 10.1186/s13075-021-02699-1

Table 2.

Associations of glucocorticoid use with APOs, PB, LBW, and LFD

APOs PB LBW LFD
APOs (+)
(n = 35)
APOs (−)
(n = 34)
P value PB (+)
(n = 14)
PB (−)
(n = 45)
P value LBW (+)
(n = 23)
LBW (−)
(n = 36)
P value LFD (+)
(n = 10)
LFD (−)
(n = 49)
P value
Glucocorticoid use, n (%)## 31 (88.6) 25 (73.5) 0.13 13 (92.9) 36 (80.0) 0.42 23 (100.0) 26 (72.2) <  0.01* 10 (100.0) 39 (79.6) 0.19
Mean glucocorticoid dose, mg/day# 9.6 ± 5.0 6.6 ± 3.7 0.03* 12.3 ± 5.5 6.7 ± 3.3 <  0.01* 9.5 ± 4.9 7.1 ± 4.2 0.05 10.0 ± 5.7 7.8 ± 4.3 0.26
Increase in the glucocorticoid dose, n (%)## 11 (31.4) 2 (5.9) 0.01* 9 (64.3) 3 (6.7) <  0.01* 9 (39.1) 3 (8.3) <  0.01* 2 (20.0) 10 (20.4) 1.00

Values are shown as mean ± standard deviation or n (%). #Wilcoxon rank sum test; ##Fisher’s exact test; *P < 0.05. APOs adverse pregnancy outcomes, PB preterm birth, LBW low birth weight, LFD light-for-date